Citations (72)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Tareq Abuasab, Jacob Rowe & Ariella Tvito. (2021) Emerging Monoclonal Antibody Therapy for the Treatment of Acute Lymphoblastic Leukemia. Biologics: Targets and Therapy 15, pages 419-431.
Read now
Read now
Marie Balsat, Victoria Cacheux, Martin Carre, Emmanuelle Tavernier-Tardy & Xavier Thomas. (2020) Treatment and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults after relapse. Expert Review of Anticancer Therapy 20:10, pages 879-891.
Read now
Read now
Prajwal Dhakal, Jasleen Kaur, Krishna Gundabolu & Vijaya Raj Bhatt. (2020) Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents?. Leukemia & Lymphoma 61:1, pages 7-17.
Read now
Read now
Francesca Del Bufalo, Pietro Merli, Iside Alessi & Franco Locatelli. (2019) B-cell depleting immunotherapies: therapeutic opportunities and toxicities. Expert Review of Clinical Immunology 15:5, pages 497-509.
Read now
Read now
Ilana R Yurkiewicz, Lori Muffly & Michaela Liedtke. (2018) Inotuzumab ozogamicin: a CD22 mAb–drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Drug Design, Development and Therapy 12, pages 2293-2300.
Read now
Read now
Mehrdad Hefazi & Mark R Litzow. (2018) Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia. Blood and Lymphatic Cancer: Targets and Therapy 8, pages 47-61.
Read now
Read now
Luciano Levato & Stefano Molica. (2018) Rituximab in the management of acute lymphoblastic leukemia. Expert Opinion on Biological Therapy 18:2, pages 221-226.
Read now
Read now
Gautam Kishore Valecha, Uroosa Ibrahim, Sassine Ghanem, Divya Asti, Jean-Paul Atallah & Terenig Terjanian. (2017) Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia. Expert Review of Hematology 10:9, pages 783-799.
Read now
Read now
Joanna Pierro, Laura E. Hogan, Teena Bhatla & William L. Carroll. (2017) New targeted therapies for relapsed pediatric acute lymphoblastic leukemia. Expert Review of Anticancer Therapy 17:8, pages 725-736.
Read now
Read now
Guru Subramanian Guru Murthy, Raji Venkitachalam & Paulette Mehta. (2015) Trends in survival outcomes of B-lineage acute lymphoblastic leukemia in elderly patients: analysis of Surveillance, Epidemiology, and End Results database. Leukemia & Lymphoma 56:8, pages 2296-2300.
Read now
Read now
Britny Rogala, Craig W Freyer, Evelena P Ontiveros, Elizabeth A Griffiths, Eunice S Wang & Meir Wetzler. (2015) Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies. Expert Opinion on Biological Therapy 15:6, pages 895-908.
Read now
Read now
Maro Ohanian, Hagop Kantarjian, Daniel Guy, Deborah Thomas, Elias Jabbour & Susan O’Brien. (2015) Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin’s lymphomas. Expert Opinion on Biological Therapy 15:4, pages 601-611.
Read now
Read now
Michael S. Mathisen, Hagop Kantarjian, Deborah Thomas, Susan O’Brien & Elias Jabbour. (2013) Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates. Leukemia & Lymphoma 54:12, pages 2592-2600.
Read now
Read now
Sarwish Rafiq, Anthony Siadak, Jonathan P. Butchar, Carolyn Cheney, Gerard Lozanski, Naduparambil K. Jacob, Rosa Lapalombella, Jackie McGourty, Meghan Moledor, Richard Lowe, Ben Setter, Jeffrey Jones, Joseph M. Flynn, Leslie Andritsos, Steven Devine, Xiaokui Mo, David Jarjoura, Susheela Tridandapani, Paul Algate, John C. Byrd & Natarajan Muthusamy. (2013) Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies. mAbs 5:5, pages 723-735.
Read now
Read now
Articles from other publishers (58)
Evangelia Kokalaki, Biao Ma, Mathieu Ferrari, Thomas Grothier, Warren Hazelton, Somayya Manzoor, Eren Costu, Julia Taylor, Anna Bulek, Saket Srivastava, Isaac Gannon, Ram Jha, Rosalind Gealy, Lukas Stanczuk, Tatiana Rizou, Mathew Robson, Mohamed El-Kholy, Vania Baldan, Matteo Righi, James Sillibourne, Simon Thomas, Shimobi Onuoha, Shaun Cordoba & Martin Pule. (2023) Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR. Molecular Therapy 31:7, pages 2089-2104.
Crossref
Crossref
David Kegyes, Ciprian Jitaru, Gabriel Ghiaur, Stefan Ciurea, Dieter Hoelzer, Ciprian Tomuleasa & Robert Peter Gale. (2023) Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia. Blood Reviews 59, pages 101042.
Crossref
Crossref
Tianyuan Ci, Wentao Zhang, Yingyu Qiao, Huangjuan Li, Jing Zang, Hongjun Li, Nianping Feng & Zhen Gu. (2022) Delivery strategies in treatments of leukemia. Chemical Society Reviews 51:6, pages 2121-2144.
Crossref
Crossref
John C. Molina & Nirali N. Shah. 2022. Clinical Management of Acute Lymphoblastic Leukemia. Clinical Management of Acute Lymphoblastic Leukemia
295
328
.
Eline J. H. van Houtum, Christian Büll, Lenneke A. M. Cornelissen & Gosse J. Adema. (2021) Siglec Signaling in the Tumor Microenvironment. Frontiers in Immunology 12.
Crossref
Crossref
Shaoming Zhu, Tian Zhang, Lei Zheng, Hongtao Liu, Wenru Song, Delong Liu, Zihai Li & Chong-xian Pan. (2021) Combination strategies to maximize the benefits of cancer immunotherapy. Journal of Hematology & Oncology 14:1.
Crossref
Crossref
Jamie L. Stokke & Deepa Bhojwani. (2021) Antibody–Drug Conjugates for the Treatment of Acute Pediatric Leukemia. Journal of Clinical Medicine 10:16, pages 3556.
Crossref
Crossref
Andrew H. Wei, Josep-Maria Ribera, Richard A. Larson, David Ritchie, Armin Ghobadi, Yuqi Chen, Abraham Anderson, Cedric E. Dos Santos, Janet Franklin & Hagop Kantarjian. (2021) Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia. Leukemia 35:8, pages 2220-2231.
Crossref
Crossref
Sebastian Zahnreich & Heinz Schmidberger. (2021) Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies. Cancers 13:11, pages 2607.
Crossref
Crossref
Hagop M. Kantarjian, Wendy Stock, Ryan D. Cassaday, Daniel J. DeAngelo, Elias Jabbour, Susan M. O'Brien, Matthias Stelljes, Tao Wang, M. Luisa Paccagnella, Kevin Nguyen, Barbara Sleight, Erik Vandendries, Alexander Neuhof, A. Douglas Laird & Anjali S. Advani. (2021) Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clinical Cancer Research 27:10, pages 2742-2754.
Crossref
Crossref
Ben Ponvilawan, Pongthep Vittayawacharin, Pattaraporn Tunsing & Weerapat Owattanapanich. (2021) Efficacy of Targeted Immunotherapy as Induction or Salvage Therapy in Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis. Technology in Cancer Research & Treatment 20, pages 153303382110374.
Crossref
Crossref
Le Li & Ying Wang. (2020) Recent updates for antibody therapy for acute lymphoblastic leukemia. Experimental Hematology & Oncology 9:1.
Crossref
Crossref
Keizo Horibe, Joan D. Morris, Catherine A. Tuglus, Cedric Dos Santos, James Kalabus, Abraham Anderson, Hiroaki Goto & Chitose Ogawa. (2020) A phase 1b study of blinatumomab in Japanese children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. International Journal of Hematology 112:2, pages 223-233.
Crossref
Crossref
Kyung Taek Hong. (2020) Immunotherapy in Pediatric Hematologic Malignant Neoplasms. Clinical Pediatric Hematology-Oncology 27:1, pages 14-21.
Crossref
Crossref
Hitoshi Kiyoi, Joan D. Morris, Iekuni Oh, Yoshinobu Maeda, Hironobu Minami, Toshihiro Miyamoto, Toru Sakura, Hiroatsu Iida, Catherine A. Tuglus, Yuqi Chen, Cedric Dos Santos, James Kalabus, Abraham Anderson, Tomoko Hata, Yasuhiro Nakashima & Yukio Kobayashi. (2020) Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia. Cancer Science 111:4, pages 1314-1323.
Crossref
Crossref
Valentin Barsan, Sneha Ramakrishna & Kara L. Davis. (2020) Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia. Current Oncology Reports 22:2.
Crossref
Crossref
Suttipong Suttapitugsakul, Fangxu Sun & Ronghu Wu. (2019) Recent Advances in Glycoproteomic Analysis by Mass Spectrometry. Analytical Chemistry 92:1, pages 267-291.
Crossref
Crossref
Seth E. Karol & Ching-Hon Pui. (2020) Personalized therapy in pediatric high-risk B-cell acute lymphoblastic leukemia. Therapeutic Advances in Hematology 11, pages 204062072092757.
Crossref
Crossref
Dalma Deak, Cristina Pop, Alina-Andreea Zimta, Ancuta Jurj, Alexandra Ghiaur, Sergiu Pasca, Patric Teodorescu, Angela Dascalescu, Ion Antohe, Bogdan Ionescu, Catalin Constantinescu, Anca Onaciu, Raluca Munteanu, Ioana Berindan-Neagoe, Bobe Petrushev, Cristina Turcas, Sabina Iluta, Cristina Selicean, Mihnea Zdrenghea, Alina Tanase, Catalin Danaila, Anca Colita, Andrei Colita, Delia Dima, Daniel Coriu, Hermann Einsele & Ciprian Tomuleasa. (2019) Let’s Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia. Frontiers in Immunology 10.
Crossref
Crossref
Bo Yu & Delong Liu. (2019) Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma. Journal of Hematology & Oncology 12:1.
Crossref
Crossref
Hiroto Inaba & Ching-Hon Pui. (2019) Immunotherapy in pediatric acute lymphoblastic leukemia. Cancer and Metastasis Reviews 38:4, pages 595-610.
Crossref
Crossref
Dongwei Li, Donna Lee, Randall C. Dere, Bing Zheng, Shang‐Fan Yu, Franklin K. Fuh, Katherine R. Kozak, Shan Chung, Daniela Bumbaca Yadav, Denise Nazzal, Dimitry Danilenko, Mary Ann T. Go, Marna Williams, Andrew G. Polson, Kirsten Achilles Poon & Saileta Prabhu. (2019) Evaluation and use of an anti‐cynomolgus monkey CD79b surrogate antibody–drug conjugate to enable clinical development of polatuzumab vedotin. British Journal of Pharmacology 176:19, pages 3805-3818.
Crossref
Crossref
Anthony S. Stein, Hagop Kantarjian, Nicola Gökbuget, Ralf Bargou, Mark R. Litzow, Alessandro Rambaldi, Josep-Maria Ribera, Alicia Zhang, Zachary Zimmerman, Gerhard Zugmaier & Max S. Topp. (2019) Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 25:8, pages 1498-1504.
Crossref
Crossref
Denis Collins, Birgit Bossenmaier, Gwendlyn Kollmorgen & Gerhard Niederfellner. (2019) Acquired Resistance to Antibody-Drug Conjugates. Cancers 11:3, pages 394.
Crossref
Crossref
Nirali N. Shah & Terry J. Fry. (2019) Mechanisms of resistance to CAR T cell therapy. Nature Reviews Clinical Oncology.
Crossref
Crossref
Helen Ma & Ahmed Sawas. (2018) Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies. Current Hematologic Malignancy Reports 13:6, pages 555-569.
Crossref
Crossref
Tania Jain & Mark R. Litzow. (2018) No free rides: management of toxicities of novel immunotherapies in ALL, including financial. Hematology 2018:1, pages 25-34.
Crossref
Crossref
Tania Jain & Mark R. Litzow. (2018) No free rides: management of toxicities of novel immunotherapies in ALL, including financial. Blood Advances 2:22, pages 3393-3403.
Crossref
Crossref
Jaclyn Rosenthal, Ammar S. Naqvi, Minjie Luo, Gerald Wertheim, Michele Paessler, Andrei Thomas-Tikhonenko, Susan R. Rheingold & Vinodh Pillai. (2018) Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia. American Journal of Hematology 93:11, pages E352-E355.
Crossref
Crossref
Fatemeh Faraji, Nader Tajik, Mahdi Behdani, Mohammad Ali Shokrgozar, Amir Hassan Zarnani, Fatemeh Shahhosseini & Mahdi Habibi-Anbouhi. (2018) Development and characterization of a camelid single-domain antibody directed to human CD22 biomarker. Biotechnology and Applied Biochemistry 65:5, pages 718-725.
Crossref
Crossref
Nirnoy Dan, Saini Setua, Vivek Kashyap, Sheema Khan, Meena Jaggi, Murali Yallapu & Subhash Chauhan. (2018) Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications. Pharmaceuticals 11:2, pages 32.
Crossref
Crossref
Troy Z. Horvat, Amanda N. Seddon, Adebayo Ogunniyi, Amber C. King, Larry W. Buie & Ryan J. Daley. (2017) The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic Leukemia. Annals of Pharmacotherapy 52:3, pages 268-276.
Crossref
Crossref
Elisabeth Paietta. 2018. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood
237
279
.
Shilpa Paul, Caitlin R Rausch, Hagop Kantarjian & Elias J Jabbour. (2017) Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin. Future Oncology 13:25, pages 2233-2242.
Crossref
Crossref
Wenjie Peng & James C. Paulson. (2017)
CD22 Ligands on a Natural
N
-Glycan Scaffold Efficiently Deliver Toxins to B-Lymphoma Cells
. Journal of the American Chemical Society 139:36, pages 12450-12458.
Crossref
Crossref
T Terwilliger & M Abdul-Hay. (2017) Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer Journal 7:6, pages e577-e577.
Crossref
Crossref
Daniel J. DeAngeloWendy StockAnthony S. SteinAndrei ShustovMichaela LiedtkeCharles A. SchifferErik VandendriesKatherine LiauRevathi AnanthakrishnanJoseph BoniA. Douglas LairdLuke FostvedtHagop M. Kantarjian & Anjali S. Advani. (2017) Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Advances 1:15, pages 1167-1180.
Crossref
Crossref
Sabine Blum, Filipe Martins & Michael Lübbert. (2017) Immunotherapy in adult acute leukemia. Leukemia Research.
Crossref
Crossref
Swapna Thota & Anjali Advani. (2017) Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia. European Journal of Haematology 98:5, pages 425-434.
Crossref
Crossref
Tobias Herold & Nicola Gökbuget. (2017) Philadelphia-Like Acute Lymphoblastic Leukemia in Adults. Current Oncology Reports 19:5.
Crossref
Crossref
Noriko Usui. 2017. Chemotherapy for Leukemia. Chemotherapy for Leukemia
123
136
.
Nosha Farhadfar & Mark R. Litzow. (2016) New monoclonal antibodies for the treatment of acute lymphoblastic leukemia. Leukemia Research 49, pages 13-21.
Crossref
Crossref
Hagop M. Kantarjian, Daniel J. DeAngelo, Matthias Stelljes, Giovanni Martinelli, Michaela Liedtke, Wendy Stock, Nicola Gökbuget, Susan O’Brien, Kongming Wang, Tao Wang, M. Luisa Paccagnella, Barbara Sleight, Erik Vandendries & Anjali S. Advani. (2016) Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. New England Journal of Medicine 375:8, pages 740-753.
Crossref
Crossref
Omar Al Ustwani, Neha Gupta, Hatoon Bakhribah, Elizabeth Griffiths, Eunice Wang & Meir Wetzler. (2016) Clinical updates in adult acute lymphoblastic leukemia. Critical Reviews in Oncology/Hematology 99, pages 189-199.
Crossref
Crossref
Hagop M. Kantarjian, Bruno Lioure, Stella K. Kim, Ehab Atallah, Thibaut Leguay, Kevin Kelly, Jean-Pierre Marolleau, Martine Escoffre-Barbe, Xavier G. Thomas, Jorge Cortes, Elias Jabbour, Susan O'Brien, Pierre Bories, Corina Oprea, Laurence Hatteville & Hervé Dombret. (2016) A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma and Leukemia 16:3, pages 139-145.
Crossref
Crossref
Binsah George, Hagop Kantarjian, Elias Jabbour & Nitin Jain. (2016) Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia. Immunotherapy 8:2, pages 135-143.
Crossref
Crossref
Musa Yilmaz, Samantha Richard & Elias Jabbour. (2015) The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia. Therapeutic Advances in Hematology 6:5, pages 253-261.
Crossref
Crossref
Boris Shor, Hans-Peter Gerber & Puja Sapra. (2015) Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Molecular Immunology 67:2, pages 107-116.
Crossref
Crossref
Elias Jabbour, Susan O’Brien, Farhad Ravandi & Hagop Kantarjian. (2015) Monoclonal antibodies in acute lymphoblastic leukemia. Blood 125:26, pages 4010-4016.
Crossref
Crossref
Nirali N. Shah, Maryalice Stetler Stevenson, Constance M. Yuan, Kelly Richards, Cindy Delbrook, Robert J. Kreitman, Ira Pastan & Alan S. Wayne. (2015) Characterization of CD22 expression in acute lymphoblastic leukemia. Pediatric Blood & Cancer 62:6, pages 964-969.
Crossref
Crossref
Elias Jabbour, Susan O'Brien, Xuelin Huang, Deborah Thomas, Michael Rytting, Koji Sasaki, Jorge Cortes, Guillermo Garcia-Manero, Tapan Kadia, Farhad Ravandi, Sherry Pierce & Hagop Kantarjian. (2015) Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. American Journal of Hematology 90:3, pages 193-196.
Crossref
Crossref
Caroline Le Jeune & Xavier Thomas. (2015) Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia. European Journal of Haematology 94:2, pages 99-108.
Crossref
Crossref
Fiona Mack, Michael Ritchie & Puja Sapra. (2014) The Next Generation of Antibody Drug Conjugates. Seminars in Oncology 41:5, pages 637-652.
Crossref
Crossref
Naval Daver & Susan O’Brien. (2013) Novel Therapeutic Strategies in Adult Acute Lymphoblastic Leukemia – A Focus on Emerging Monoclonal Antibodies. Current Hematologic Malignancy Reports 8:2, pages 123-131.
Crossref
Crossref
Hagop KantarjianDeborah ThomasAlan S. WayneSusan O'Brien. (2012) Monoclonal Antibody-Based Therapies: A New Dawn in the Treatment of Acute Lymphoblastic Leukemia. Journal of Clinical Oncology 30:31, pages 3876-3883.
Crossref
Crossref
S Rafiq, C Cheney, X Mo, D Jarjoura, N Muthusamy & J C Byrd. (2012) XmAb-5574 antibody demonstrates superior antibody-dependent cellular cytotoxicity as compared with CD52- and CD20-targeted antibodies in adult acute lymphoblastic leukemia cells. Leukemia 26:7, pages 1720-1722.
Crossref
Crossref
Hagop Kantarjian, Deborah Thomas, Jeffrey Jorgensen, Elias Jabbour, Partow Kebriaei, Michael Rytting, Sergernne York, Farhad Ravandi, Monica Kwari, Stefan Faderl, Mary Beth Rios, Jorge Cortes, Luis Fayad, Robert Tarnai, Sa A Wang, Richard Champlin, Anjali Advani & Susan O'Brien. (2012) Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. The Lancet Oncology 13:4, pages 403-411.
Crossref
Crossref
Stefania Paolini, Anna Gazzola, Elena Sabattini, Francesco Bacci, Stefano Pileri & Pier Paolo Piccaluga. (2011) Pathobiology of acute lymphoblastic leukemia. Seminars in Diagnostic Pathology 28:2, pages 124-134.
Crossref
Crossref